Clear Program Physician Webpage
Information specifically for physicians to help your patient understand PAD. Learn More »
Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1 Now, Abbott's Esprit™ BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. With reduced restenosis and reinterventions,3,6,7 and significant improvement in primary patency and limb salvage,3,6 you can be confident you're giving your patients the state-of-the-art standard of care.
Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,4 combined with a drug to inhibit neointimal hyperplasia,5 and then fully resorbs over time,9 preserving future treatment options.
Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.
See the Vascular Health Economics and Reimbursement website for additional resources
The material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guaranteed that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and therfore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.
Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights.
Diameter | 18 | 28 | 38 | Sheath (F)1 | Maximum Post-Dilation Diameter1 | Nominal/RBP Inflation Pressure4 |
---|---|---|---|---|---|---|
2.5 mm | 1203250-18 | 1203250-28 | 1203250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
3.0 mm | 1203300-18 | 1203300-28 | 1203300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
3.5 mm | 1203350-18 | 1203350-28 | 1203350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
3.75 mm | 1203375-18 | 1203375-28 | 1203375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
This device is commercially available for use in select international markets. Check the regulatory status in your geography.
MAT-2405960 v4.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0